Agreement between CAUL Consortium and Elsevier
Elsevier and CAUL Consortium have established an agreement to support authors in Australia and New Zealand, who wish to publish open access.
The cost of publishing open access is covered under the terms of this agreement. When publishing open access in eligible hybrid journals, eligible corresponding authors, from institutions participating in the CAUL agreement, do not have to pay an article publishing charge (APC).
How does the process work?
The process of publishing under the agreement is straightforward:
Step 1 – Once the journal accepts your article, you will receive an email containing a link to the “post acceptance author journey”.
Step 2 – You will be asked to review your affiliation and funder details. Based on this information, you will see personalised publishing options including the option to publish under the agreement.
Step 3 – You will confirm your publishing choices and complete the post acceptance journey.
Step 4 – CAUL will validate your eligibility for the agreement
Step 5 – You and your co-authors will receive an email to confirm that the APC will be covered by the agreement. Please note that the number of APCs included under the agreement is fixed and will be allocated based on date of acceptance.
During the submission process, the system will present you with personalised publishing options including any agreement or offer that you may be eligible for. You can indicate your publishing choice during submission, but you are not required to finalize your choice until after acceptance.
Which institutions are covered by this agreement?
This agreement supports corresponding authors (see FAQ at the bottom of this page) affiliated with the CAUL Consortium.
Which journals are included in this agreement?
Authors can publish eligible articles (see FAQ at the bottom of this page) in a selected list of titles within Elsevier’s portfolio of journals.
What are the author benefits of publishing open access with Elsevier?
When you publish open access with Elsevier, you get the attention you deserve. We offer authors:
Choice – We have open access journals across every scientific discipline.
Support – Receive expert support throughout submission, during peer review, and post-acceptance.
Visibility – Your final published article will be published on ScienceDirect, the number one research platform in the world.
To learn more about the benefits of publishing open access with Elsevier visit our Open Access Author Hub.
Are there other publishing options?
Authors can continue to choose to publish under the subscription model which includes the option to self-archive their manuscript (Green Open Access) in line with Elsevier’s sharing policy.
Articles must have an original acceptance date between 1 January 2023 and 31 December 2025.
The corresponding author is the person who submits the manuscript and other related documentation to the journal and is the primary contact between the journal and all other authors. If the paper is published, the corresponding author is also the first point of contact for readers.
The corresponding author’s responsibilities include:
Ensuring that all authors have complied with the journal’s policies, including reviewing and approving the final version of the manuscript prior to submission
Distributing and responding to communications from the journal (e.g., decision letters, reviewers’ reports)
Completing the post publication author journey including the Journal Publishing Agreement, Rights and Access information form and selection of open access options on behalf of, and with the agreement of, the co-authors
Dealing with any post-publication correspondence (e.g., providing information regarding research data, methods and resources).
Corresponding authors should ensure they use their institutional email address for the affiliated institution, failure to do so may result in the request for OA being rejected by CAUL.
For the purposes of the agreement, there is only one corresponding author. All other authors that are not corresponding authors, are called ‘co-authors’.
With this agreement, authors have a choice between a commercial (CC BY) or non-commercial (CC BY-NC-ND) license. The license choice is dependent on the journal selected. Please refer to the journal's homepage for specific details.
The following article types are part of this agreement: